Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing challenges.

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are among the top drugmakers planning price increases for hundreds of ...

The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions.

A great dividend stock is one that's supported by a financially healthy, stable, and mature company with a proven commitment ...